Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Anal Cancer Metastatic × Gemcitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 56 Nasopharyngeal Carcinoma 22 Cholangiocarcinoma 19 Biliary Tract Neoplasms 19 Urinary Bladder Neoplasms 18 Carcinoma, Non-Small-Cell Lung 16 Neoplasm Metastasis 14 Breast Neoplasms 14 Lung Neoplasms 12 Carcinoma, Transitional Cell 11 Lymphoma, Large B-Cell, Diffuse 10 Colorectal Neoplasms 10 Recurrence 9 Non-Muscle Invasive Bladder Neoplasms 9 Sarcoma 8 Neoplasms 6 Hodgkin Disease 6 Gallbladder Neoplasms 6 Ovarian Neoplasms 5 Adenocarcinoma 5 Uterine Cervical Neoplasms 4 Nasopharyngeal Neoplasms 4 Leiomyosarcoma 4 Triple Negative Breast Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Pancreatic Adenocarcinoma 3 Osteosarcoma 3 Lymphoma, T-Cell, Peripheral 3 Lymphoma, B-Cell 3 Lymphoma 3

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07280377 2025-12-12

GOBLET

Oncolytics Biotech

Phase 1/2 Recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡